SCHEMBL1906715

SCHEMBL1906715

CC(=O)On1c2ccccc2c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
GPR3 P46089 1/20 0.43
KDM4E B2RXH2 5/20 0.42
LMNA P02545 3/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 4/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTPN1 P18031 1/20 0.40
FABP3 P05413 1/20 0.40
FABP4 P15090 1/20 0.40
FABP5 Q01469 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NR4A2 P43354 1/20 0.40
TSPO P30536 1/20 0.40
EGFR P00533 1/20 0.40
SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373253 0.90 P2RX4 (0.47) POLBKDM4EMAPTHTTALDH1A1
SCHEMBL27996393 0.82 POLB (0.42) POLBGPR3KDM4ELMNAMAPT
SCHEMBL7073898 0.81 POLB (0.48) POLBGPR3KDM4ELMNAMAPT
SCHEMBL9678983 0.80 POLB (0.47) POLBGPR3KDM4ELMNAMAPT
SCHEMBL27620887 0.79 EGFR (0.45) POLBKDM4EMAPTALDH1A1GAA
SCHEMBL8431590 0.79 PARP1 (0.44) POLBKDM4EHTTALDH1A1GAA
SCHEMBL28954177 0.79 KDM4E (0.47) POLBGPR3KDM4ELMNAMAPT
SCHEMBL28208567 0.79 POLB (0.46) POLBKDM4ELMNAMAPTALDH1A1
SCHEMBL30254498 0.78 DDB1 (0.41) POLBHTTALDH1A1HSD17B10PTPN1
SCHEMBL5316843 0.78 MAOB (0.50) NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104345368-B Elliptical polarization plate 住友化学株式会社 2018-10-16 CN disclosed
CN-108196323-A The activation method and manufacturing method of optical thin film, optical thin film and image display device 日东电工株式会社 2018-06-22 CN disclosed
US-9186365-B2 Antiangiogenic small molecules and methods of use THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2015-11-17 US disclosed
US-20120129775-A1 ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2012-05-24 US disclosed
EP-2316824-A1 (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates Actelion Pharmaceuticals Ltd. (CH) 2011-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129775-A1 ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE VEGFA, FLT4, KDR POLB 1537/4885GPR3 2835/4885KDM4E 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.